SCHEMBL17015657

SCHEMBL17015657

c1ccc(-c2ccc(-n3ccc4c3ccc3c5ccccc5n(-c5ccc(-c6ccc7cc8ccccc8cc7c6)cc5)c34)cc2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.35
ATM Q13315 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
NR3C1 P04150 1/20 0.34
BIRC5 O15392 1/20 0.33
MAOB P27338 1/20 0.32
ESR1 P03372 2/20 0.32
ESR2 Q92731 2/20 0.32
HTR7 P34969 1/20 0.32
HDAC4 P56524 1/20 0.32
HSD17B1 P14061 2/20 0.31
HSD17B2 P37059 2/20 0.31
RXRA P19793 1/20 0.31
RXRB P28702 1/20 0.31
HTR6 P50406 1/20 0.31
PIK3CD O00329 1/20 0.31
PIK3CA P42336 1/20 0.31
MTOR P42345 1/20 0.31
TUBB4A P04350 1/20 0.31
TUBB P07437 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17016140 0.98 KDM4E (0.38) KDM4EATML3MBTL1NR3C1BIRC5
SCHEMBL17015193 0.98 KDM4E (0.38) KDM4EATML3MBTL1NR3C1BIRC5
SCHEMBL17015658 0.95 WNK1 (0.33) KDM4EATML3MBTL1NR3C1BIRC5
SCHEMBL17015739 0.95 NR3C1 (0.33) KDM4EATML3MBTL1NR3C1MAOB
SCHEMBL17015659 0.94 MAPK9 (0.33) KDM4EATML3MBTL1NR3C1BIRC5
SCHEMBL17015649 0.93 PDPK1 (0.35) KDM4EATML3MBTL1NR3C1BIRC5
SCHEMBL17016142 0.92 L3MBTL1 (0.37) KDM4EATML3MBTL1HSD17B1HSD17B2
SCHEMBL17015194 0.92 KDM4E (0.34) KDM4EATML3MBTL1HSD17B1HSD17B2
SCHEMBL17016132 0.91 KDM4E (0.38) KDM4EATML3MBTL1NR3C1BIRC5
SCHEMBL17015181 0.91 KDM4E (0.38) KDM4EATML3MBTL1NR3C1BIRC5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME INMT, IDO1, IDO2 KDM4E 1286/4885ATM 3623/4885L3MBTL1 533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.